October 25, 2013
The D.C. Circuit on Tuesday shot down a bid from a U.S. unit of Japan's Eisai Co. Ltd. to force the U.S. Drug Enforcement Administration to speed up the process for scheduling its epilepsy drug Fycompa as a controlled substance, saying the company had not shown the need for such drastic action.